Montanova Capital LLC Acquires 376,000 Shares of Zura Bio Limited $ZURA

Montanova Capital LLC increased its holdings in Zura Bio Limited (NASDAQ:ZURA) by 4.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,443,001 shares of the company’s stock after purchasing an additional 376,000 shares during the period. Zura Bio accounts for 0.9% of Montanova Capital LLC’s holdings, making the stock its 28th biggest holding. Montanova Capital LLC owned 9.95% of Zura Bio worth $55,714,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ZURA. Suvretta Capital Management LLC raised its position in shares of Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after buying an additional 94,110 shares during the last quarter. VR Adviser LLC grew its stake in Zura Bio by 15.4% during the fourth quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock valued at $28,008,000 after acquiring an additional 713,899 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Zura Bio by 78.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the last quarter. Siren L.L.C. lifted its stake in Zura Bio by 187.3% in the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after purchasing an additional 2,434,866 shares in the last quarter. Finally, Commodore Capital LP purchased a new position in shares of Zura Bio during the first quarter valued at about $19,338,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZURA has been the topic of several research reports. Guggenheim lifted their target price on Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Wedbush upped their price objective on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research report on Monday, July 6th. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, William Blair assumed coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Zura Bio Trading Down 3.1%

Shares of NASDAQ:ZURA opened at $5.54 on Tuesday. The company has a market cap of $530.90 million, a price-to-earnings ratio of -4.90 and a beta of -0.02. Zura Bio Limited has a 12 month low of $1.88 and a 12 month high of $7.44. The company has a 50-day moving average price of $5.47 and a 200 day moving average price of $5.38.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.21) earnings per share for the quarter. As a group, equities analysts forecast that Zura Bio Limited will post -0.81 EPS for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.